BioPharma Resources

Drug Trial Radar · NCT01509508

Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence

A Cluster Randomised Trial Comparing the Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence. The ARNS 12249 TasP (Treatment as Prevention) Trial in Hlabisa Sub-district, KwaZulu-Natal, South Africa.

Last checked: Nov 19, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 28,153 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

28,153

Actual

Start

Mar 2012

Primary completion

Jun 2016

Study completion Jun 2016

Sponsor

Lead sponsor
ANRS, Emerging Infectious DiseasesGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
Africa Centre For Health and Population Studies; University of KwaZulu
First posted
Jan 13, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 16 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This trial is evaluating a public health intervention strategy trial which aims to reduce the incidence of HIV at a population-level. The proposed strategy is a two steps process: * Extensive HIV counselling and testing, and comprehensive prevention programme among a target population * Immediate ART initiation after HIV diagnosis, irrespective of CD4 count criteria. The underlaying trial hypothesis is that HIV testing followed by immediate ART initiation of all HIV-infected individuals will prevent onward transmission and reduce HIV incidence in the population. This is a cluster randomised controlled trial with a total of 22 communities used as the units for randomisation. Enrolment of a population of 22 000 individuals among which 4 400 are expected to be HIV-Infected.

Conditions

  • HIV Infection

Interventions

  • Immediate ARV treatment initiation with TDF/FTC/EFVDrug

    All HIV-infected adults will be offered ART regardless of their immunological and clinical staging. The first line regimen proposed will be Atripla (R), a fixed dose combination containing tenofovir disoproxil (245 mg)/emtricitabine (200 mg)/efavirenz (600 mg)(FTC/TDF/EFV). The dosing will be 1 tablet OD.

  • South African recommendation guided ARV (TDF/FTC/EFV) initiationOther

    HIV-infected adult participants will be eligible for ART as per the South African guidelines (August 2011) if: * CD4 count ≤ 350 cells/mm3 irrespective of clinical symptoms * WHO clinical stage 3 or 4 irrespective of CD4 count * MDR or XDR TB The first line regimen proposed will be Atripla (R), a fixes dose combination containing tenofovir disoproxil (245 mg)/emtricitabine (200 mg)/efavirenz (600 mg)(TDF/FTC/EFV). The dosing will be 1 tablet OD.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Uptake of initial and repeat HIV counselling and testing (Feasibility phase)Time frame: 14 months
  2. Uptake of ARV treatment among HIV-infected individuals (Feasibility phase)Time frame: 14 months
  3. HIV infection incidenceTime frame: 4 years after enrolment initiation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hlabisa Hospital

    Hlabisa, KwaZulu-Natal, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.